Cortexyme is developing treatments for Alzheimer's and other degenerative disorders.
Cortexyme is a clinical stage pharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currently testing several potential lead therapeutics in preclinical studies.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
May 31, 2018 | Series B | $76M | 3 | Sequoia Capital | — | Detail |
Apr 14, 2017 | Debt Financing | $8M | 2 | — | — | Detail |
Jan 6, 2016 | Series A | $15M | 1 | Pfizer | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Sequoia Capital | Yes | Series B |
Verily | — | Series B |
Lamond Family | — | Series B |
Pfizer | — | Debt Financing |